QSurface

QSurface: Identification of Subtype-Specific Over-Expressed Surface Antigens in Cancer

QSurface identifies over-expressed cell surface antigens specific to cancer subtypes or mutations by profiling patient-derived transcriptome data and performing lineage/mutation-oriented statistical analysis.

Key Features:

• Surface Gene Profiling: Profiles expression of 519 genes encoding cell surface proteins across 14 cancer subtypes using patient-derived transcriptome datasets.
• Lineage/Mutation-Oriented Analysis: Applies statistical methods to validate subtype- or mutation-specific surface markers.
• Protein-Level Validation: Experimentally confirms over-expression of markers including MUC4, MSLN, and SLC7A11 in lung cancer cells.
• 3D Cell Line Modeling: Utilizes advanced 3D lung cell line models to reproduce predicted expression patterns and assess physiological relevance.

Scientific Applications:

• Biomarker Discovery: Identifies novel subtype-specific surface antigens for diagnostic and therapeutic targeting.
• Targeted Therapy Development: Supports antigen selection for antibody-drug conjugates (ADCs) and other selective cancer therapies.
• Personalized Oncology: Enables analysis of patient-specific transcriptomic profiles to inform mutation- or subtype-guided treatment strategies.

Methodology:

QSurface selects 519 cell surface protein genes and quantifies their expression in patient-derived transcriptome data across 14 cancer subtypes. It applies lineage/mutation-oriented statistical analyses to detect subtype-specific over-expression patterns. Candidate markers are validated experimentally at the protein level, including in 3D lung cell line models to confirm physiological relevance.